Industry news that matters to you.  Learn more

Archives for February 2016

PROOF Centre Collaboration Focuses on Prognostic Biomarkers for Chronic Kidney Disease

The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) recently announced a new partnership with AstraZeneca and the Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT) to develop a blood test to predict the rate of disease progression in patients with chronic kidney disease (CKD).

Invivoscribe Announces Long-Term Collaboration to Develop Immuno-Oncology Tests With Thermo Fisher Scientific

Invivoscribe® Technologies, Inc., a global company that provides international access to personalized molecular diagnostics, today announces it has signed a long-term strategic collaboration agreement with Thermo Fisher Scientific to develop multiple next-generation sequencing (NGS)-based, in vitro diagnostic (IVD) oncology tests on the Ion PGMTM Dx System.

Protagen Supports Novel Route to Serum-based Prostate Cancer Diagnostics

Protagen AG, technology leader in the development of novel molecular diagnostic and companion diagnostic tests for autoimmune diseases and oncological indications, recently announced the identification of novel protein biomarkers in prostate cancer, which are potential drug targets supporting novel strategies in precision medicine. Using the proprietary Protagen SeroTag® technology, the discovery was made in close collaboration with Professor Helmut Klocker, Medical University of Innsbruck and Oncotyrol Center for Personalized Cancer Medicine, Innsbruck, and Professor Mark Rubin, Cornell University and Targos Molecular Pathology GmbH, Kassel.

$1 Million Investment to Launch Grand Challenge to Develop a TDP43 Biomarker

The ALS Association, in partnership with ALS Finding a Cure, is pleased to announce the Grand Challenge to generate a biomarker to track TDP43 aggregation. The successful team(s) with the most developed plan will receive up to a $1 million investment.

GenePool from Station X to Help Epic Sciences Analyze Circulating Tumor Cell Data

Station X, Inc., a pioneer in solving big data analytics and platform integration challenges for customers engaging in genomics-based clinical research and medical applications, recently announced that Epic Sciences will use its GenePool® platform to facilitate data interpretation and collaboration with biopharmaceutical companies developing companion diagnostics based on the company’s innovative circulating tumor cell (CTC) technology.